Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Working Capital Changes (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Working Capital Changes for 2 consecutive years, with -$678446.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 61.52% to -$678446.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $180115.0, a N/A change, with the full-year FY2025 number at $453058.0, up 3886.84% from a year prior.
  • Other Working Capital Changes was -$678446.0 for Q4 2025 at Neuphoria Therapeutics, down from -$34793.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $654861.0 in Q2 2025 to a low of -$678446.0 in Q4 2025.